24/7 Market News Snapshot 26 December, 2024 – Hoth Therapeutics, Inc. Common Stock (NASDAQ:HOTH)

December 26, 2024

DENVER, Colo., 26 December, 2024 (247marketnews.com) – (NASDAQ:HOTH) are discussed in this article.
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a pioneering biopharmaceutical firm focused on innovative therapeutic solutions, has made headlines with its entry into a significant patent license agreement with the U.S. Department of Veterans Affairs (VA) and Emory University. This strategic collaboration grants Hoth the rights to a groundbreaking patent portfolio centered around “Glial Cell Line-Derived Neurotrophic Factor,” with the aim of addressing obesity and related health conditions.

As Hoth embarks on this promising venture, it seeks to develop, market, and commercialize products derived from this newly licensed technology. Robb Knie, Chief Executive Officer of Hoth Therapeutics, expressed enthusiasm regarding the partnership, emphasizing its importance in the company’s mission to combat obesity through scientifically driven methodologies. Knie stated, “This agreement represents a pivotal step forward in our efforts to provide effective solutions for obesity and its associated health risks. Our collaboration with both the VA and Emory University will help translate innovative research into practical outcomes for patients.”

As trading commenced today, Hoth shares opened at $0.81 but have since dipped to approximately $0.763, reflecting a decline of 3.05%. This follows the previous session’s close at $0.787, indicating ongoing selling pressure. The trading volume has been significant, reaching 8.12 million shares, suggesting heightened investor interest and potential volatility. Technical analysis reveals critical support levels around $0.75, with resistance observed at approximately $0.79.

In addition to the licensing agreement, Hoth is advancing its intellectual property strategy, including a letter of intent to acquire further provisional patent protection for its lead therapeutic, HT-001. This multidimensional approach underscores Hoth’s commitment to translating scientific discoveries into impactful therapeutic options, thereby enhancing patient care and addressing unmet medical needs globally.

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.